Form D · Pharmaceuticals

EPALEX Corp

Mountain View, CA · CIK 0001755010

Offering snapshot reported Nov 10, 2025 · SEC filing

Reported sold
$1.2M
Offering amount: $3.2M
Investors reported
1
Form D · investor count
Minimum accepted
$0
Reported outside-investor minimum
First sale
Oct 31, 2025
As reported in this filing

What changed?

Latest filing versus its linked predecessor, where available.

No comparable changes in the displayed metrics.

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Nov 10, 2025Initial$1,200,000No comparison1SEC filing
Dec 20, 2024Initial$3,999,999No comparison1SEC filing
Oct 14, 2022Initial$4,260,617No comparison15SEC filing
Dec 18, 2020Amendment$20,296,275$10,297,905vs Jan 10, 20197SEC filing
Jan 10, 2019Initial$9,998,370No comparison1SEC filing
Nov 20, 2018Initial$999,284No comparison5SEC filing

Offering details

Securities
Equity
Exemptions
06b
Duration over one year
No
Business combination
No
Sales commissions
$0
Finders' fees
$0
Form D file number
021-563583

Source: Form D, filed Nov 10, 2025. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No matching detailed fund disclosure was found in the latest imported ADV filings. This does not establish that the issuer has no adviser.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
Enrique J Carrazana Director
Didric Cedarholm Director
Didric Cederholm Director
Steven F Lincoln Executive
Brendan Magrab Director, Executive
Randall Murphy Director
Arthur Franklin Rice Director, Executive
Michael Rogawski Director
Jon Saxe Director
Matthew Smith Director

Issuer details

Industry: Pharmaceuticals (See others in industry)

Address:
1049 El Monte Avenue, Suite C 585
Mountain View, CA, 94040
Phone: 659-946-3366 X700